Disposition of 1996 shares by Bizily Scott of 4D Molecular at 25.0 subject to Rule 16b-3
| FDMT Stock | USD 4.54 0.02 0.44% |
Slightly above 62% of 4D Molecular's investor base is looking to short. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that many traders are alarmed. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
FDMT |
Filed transaction by 4D Molecular Therapeutics Officer: Chief Legal Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
4D Molecular Fundamental Analysis
We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
4D Molecular is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
4D Molecular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.
Peers
4D Molecular Related Equities
| MLYS | Mineralys Therapeutics, | 10.50 | ||||
| PASG | Passage Bio | 1.92 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| AKRO | Akero Therapeutics | 0.25 | ||||
| STOK | Stoke Therapeutics | 0.24 | ||||
| REPL | Replimune | 0.88 | ||||
| NVCT | Nuvectis Pharma | 1.01 | ||||
| CGEM | Cullinan Oncology | 1.29 | ||||
| IPSC | Century Therapeutics | 1.43 | ||||
| KRON | Kronos Bio | 2.00 | ||||
| RVMD | Revolution Medicines | 2.03 | ||||
| GOSS | Gossamer Bio | 3.08 | ||||
| LYRA | Lyra Therapeutics | 4.76 | ||||
| CCCC | C4 Therapeutics | 5.02 | ||||
| BDTX | Black Diamond | 6.45 | ||||
| BMEA | Biomea Fusion | 14.97 |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.